Ophthalmic transplantology: Posterior segment of the eye – Part II

Małgorzata Nita¹, Barbara Strzałka-Mrozik², Andrzej Grzybowski¹³⁻⁴, Wanda Romaniuk⁵, Urszula Mazurek²

¹ Domestic and Specialized Medicine Centre “Dilmed,” Katowice, Poland
² Department of Molecular Biology, Medical University of Silesia, Sosnowiec, Poland
³ Department of Ophthalmology, Poznan City Hospital, Poznan, Poland
⁴ Medical Faculty, University of Warmia and Mazury, Olsztyn, Poland
⁵ Department of Ophthalmology, Medical University of Silesia, Independent Public Clinical Hospital, Katowice, Poland

Source of support: The work was supported by Medical University of Silesia, Katowice, Poland (KNW-1-059/P/1/0)

Summary

Background: Transplants of the retina are among the new strategies being used in the treatment of genetic and degenerative macular diseases. Moreover, various cell cultures are being tested to treat retinal disorders.

Material/Methods: Literature dated from 2004 to 2011 was comprehensively examined via Medline and PubMed searches for the following terms: auto-, homo-, heterologous transplantation, retina, stem cells, cultivated cells.

Results: Tissue and cell therapy of retinal diseases are reviewed, including full-thickness retina/retinal pigment epithelium (RPE)/choroid graft; full and partial thickness RPE/choroid complex grafts; RPE/Bruch membrane complex graft; and RPE, iris pigment epithelium and stem cell grafts. Recommendations for transplants, as well as the benefits and weaknesses of specific techniques in retina transplants, are discussed.

Conclusions: Auto- and allogenic transplants of a full or partial thickness retina/RPE/ Bruch membrane/choroid complex represent an alternative treatment offered to patients with some macular diseases. Stem cell transplantation to reconstruct and regenerate the macula requires further biomolecular and animal research studies.

key words: eye ball • transplantation • autologous • homologous • heterologous • retina • stem cells

Full-text PDF: http://www.medscimonit.com/fulltxt.php?ICID=882868

Word count: 3846

Tables: –

Figures: –

References: 93

Author’s address: Andrzej Grzybowski, Jozef Strus Poznan City Hospital, Department of Ophthalmology, Szwajcarska 3 St., 61-285 Poznan, Poland, e-mail: ae.grzybowski@gmail.com
**BACKGROUND**

Genetic and degenerative retinal diseases currently present scientific and ophthalmological challenges. In the United States, approximately 6 million people have retinal diseases, in particular from retinopathies such as age-related macular degeneration (AMD), diabetic retinopathy and retinitis pigmentosa [1–3]. AMD accounts for 75% of cases of legal blindness in people over the age of 50 years in all industrialized countries [4,5]. Photodynamic therapy or intravitreal anti-vascular endothelial growth factor (VEGF) injections represent the first line of wet AMD treatment, but are of limited efficacy [4–8]. No treatment has been proposed for atrophic maculopathy [9,10]. Implantation of electronic chips to stimulate the brain, as well as transplantation of donor tissue and cells, are new therapeutic strategies currently being explored to reconstruct the photoreceptor/retinal pigment epithelium (RPE) complex and to restore central vision in different retinopathies [11–14].

An animal model of retinal degeneration demonstrated the importance of the survival and integration of transplanted tissues [15]. The human eye is an immune-privileged organ – an evolutionary phenomenon that prevents immunogenic inflammation, macular destruction and blindness [12,13,16–18]. Blood-tissue barriers that limit the ingress of blood-borne immunogenic factors; immunosuppressive properties of pigment epithelial cells; and the expression of CD95 ligand on ocular parenchymal cells, which triggers the apoptosis of effector T cells, all contribute to the immune tolerance of the eye [19,20]. Human RPE cells have the particular ability to suppress T-cell activity by direct contact (Toll-like receptors serve as the first line of defense [1–7,9,10]) and via secretion into the aqueous humor and vitreous body of soluble immunomodulatory/suppressive factors, such as cytotoxic T lymphocyte-associated antigen-2α programme cell death 1 ligand, thrombospondin-1 and transforming growth factor [19,21–25]. These overlapping mechanisms enable acceptance of foreign tissue grafts for extended intervals – unlike conventional body sites that summarily reject such grafts – and delay symptoms of retinal rejection (ie, shrinkage, architecture loss and glial transformation accompanied by low-grade inflammation) [19,26].

**TISSUE THERAPY IN RETINAL DISEASES**

Full-thickness retina/RPE/choroid complex allogenic grafts were performed to treat patients with retinitis pigmentosa and geographic atrophy in dry AMD [27,28]. During a 5-year study, graft samples were harvested from the enucleated eyes of human embryos after abortion in the 10th to 15th week of pregnancy [28]. An average tissue area of 3.5 mm² was excised directly before the transplantation. It was then placed in a special applicator (allowing gentle lifting and correct direction of the tissue) and grafted under the central retina by means of an upper nasal retinotomy. The procedure was finalized by applying the laser around the host/donor interface, may have contributed to better visual acuity [28]. The "new immunization" was not found in human leukocyte antigens; embryonic tissues were less immunogenic and the blood-brain barrier stopped the infiltration of the graft’s antigens [28]. Five years after surgery, no graft rejection symptoms, such as macular edema or encapsulation, were found clinically or by optical coherence tomography. However, in the graft area, pigment loss occurred in 80% of patients after 3–6 months, which was not interpreted as rejection because of the improvement in visual acuity [28]. The investigators also suggested that the improvement could result not only from the graft, but also from the lensectomy and vitrectomy, which had been performed before transplantation during the same procedure [30]. The administration of neutrophins (an indirect result) rather than the replacement of the degenerated tissue could also have contributed to the good results. It is doubtful, however, whether this type of graft would be commonly accepted (because of ethical and religious dilemmas) [30].

Autotransplantation (autotranslocation) of RPE/choroid complex graft is called a full-thickness autologous patch or a patch graft (PG). Such grafts were performed in patients with wet AMD (choroidal neovascularization in AMD [CNV/AMD]) [31–35], RPE rip [36] and dry AMD (geographic atrophy in AMD) [37]. A PG consists of the RPE, Bruch membrane, and choriocapillaris, as well as medium and large choroidal vessel translocation [31,32]. The differences between PG methods [31,32] depend on the manner in which the neovascular tissue is removed and the graft is prepared, as well as on the tissue translocation technique used (see below). One method involved the removal of CNV by means of perimacular retinotomy and harvesting of the graft from the superior temporal equatorial retina [31,35]. It was first encircled with continuous laser impacts and then excised as deep as the sclera with vertical scissors. The retina was peeled from the sheet and PG was implanted under the fovea through a central retinotomy. The procedure was finalized by applying the laser around the retinotomy and performing a perfluorocarbon-oil exchange. One study [31] compared the results of this PG technique with those of full macular translocation (FMT) surgery (360°). The results after 1 year were comparable, but after 4 years the results of FMT surpassed those of PG (the deterioration of visual acuity from 0.87 to 1.38 logMAR in PG and from 0.9 to 0.99 logMAR in FMT; more extensive RPE damage and inferior fixation occurred in the PG group) [31]. Three reasons for the inferior results in the PG group have been suggested [31]: (1) Iatrogenic detachment of the retina caused by the fluid in FMT does not damage the natural, strong adhesion of the photoreceptors and RPE to the extent that peeling does; (2) in PG, the tissue is harvested from the equatorial retina and RPE, which is less specific and less sensitive than paramacular RPE, on which the retina is placed and rotated by 45° in FMT; and (3) the perfusion disorder can last for several days after PG and the translocation of the full choroid section does not prevent ischemia and does not contribute to the metabolic balance of the retina [31]. In another study [35] the investigators compared results of autologous RPE/choroid PG with an RPE cell-suspension graft. Three or more lines...
in best corrected visual acuity at 24 months follow-up was found in 28.5% of patients in the RPE patch group and in 14.2% of patients in the RPE cell-suspension group; a loss of 3 or more lines occurred in 14.2% in each group (n=7 in each group) [35]. Examination by fluorescein and indocyanine green angiography showed revascularization of all PGs and normal choroidal vasculature in the area of RPE atrophy in all patients of the RPE cell-suspension group. However, part of the successfully transplanted patch grafts showed intrastructural changes on spectral-domain optical coherence tomography (ie, irregularities in the cell layers; scarring or glialis and an absence of photoreceptors and outer nuclear layer) [35]. This may explain the limited visual gain of RPE PGs, which should theoretically be a better option than RPE suspension grafts (loose, unevenly distributed RPE cells without their own basal lamina are worse support for photoreceptors than a functional monolayer in sheet grafts) [35]. In another method for PG surgery, a temporal 180° retinotomy was performed and the mobilized retina placed on the nasal area [32]. The vast retinal area bared in this way enabled less extensive CNV removal. With special scissors, the graft was excised from the central circumference of the fundus in the superior temporal quadrant and was not encircled by the laser. In cases of hemorrhage, the nutrient vessel supporting the graft was coagulated with diathermia and/or the intraocular pressure was raised. The retina was sealed from the sheet. Perfluorocarbon injected into the subretinal area stabilized the folded retina and allowed for autotranslocation. Moreover, perfluorocarbon injected into the intrinsic surface reversed the retina and stabilized the graft. The procedure was finalized by applying a laser along the retinotomy and by performing a perfluorocarbon-oil exchange. Between 4 and 20 months after surgery, visual acuity improved in 60% of eyes, stabilized in 30% and deteriorated in 10% (n=13) [32].

The advantage of the technique is the easy access to the posterior area. This allows for delicate CNV excision and maximum preservation of residual, healthy RPE and subretinal vessels; in addition, it enables and accelerates revascularization of the graft [32]. Folding and stretching of the tissue during implantation was not required (it took place in the graft through paramacular retinotomy) [32]. The laser was not used prior to tissue resection to avoid the shrinkage and infolding of the graft’s edges. It is vital for the graft to be large enough to entirely cover the area of the recipient’s damaged RPE and choroid [32]. The tissue junction contributes to the nutrient bridge vessel at the host/donor interface and to early graft revascularization [32]. In indocyanine green angiography, the graft’s nutrient vessels did not run radially, but in parallel as ladder rungs [32]. Moreover, proliferative vitreous retinopathy (PVR) did not occur in this group [32]. PVR occurs in 20–50% of patients after a 360° retinotomy and in 31% of patients after paramacular retinotomy; a large incision area and good perfusion of the central retina lead to PVR [38]. Lack of PVR in the above-mentioned group is ascribed to limited (180°) retinotomy in the poorly vascularized circumferential area of the retina and routine performance of phacoemulsification with intraocular lens implantation [32]. The right access allows for maximum excision of the vitreous base, which prevents shrinkage and PVR [32].

In some patients, the long-term results are not satisfactory after PG [35,39]. Extensive tissue thickness makes penetration of nutrients and reperfusion difficult, thereby leading to graft fibrosis beginning just 30–60 days after autotranslocation [39]. Animal research has shown that a partial graft, with no medium and large choroid vessels, is easily integrated with the recipient’s bed. In 65% of the animals, the partial graft was found to be viable (ie, revascularization and monolayered RPE cells were present) [40].

**Autologous RPE/Bruch membrane complex grafts** were performed in patients with hemorrhagic CNV in wet AMD [38]. A temporal 180° retinotomy was performed with CNV removal on the external side of the retina and laser around the retinotomy with a perfluorocarbon-oil exchange. The 4 mm² graft was excised with a microvitreoretinal knife on the cauterized area from the central circumference in the superior temporal quadrant. The incision was as deep as the middle choroid. The RPE/Bruch membrane complex was separated from the choroid vessels with a special S-shaped spatula and scissors [38]. Patients showed improved Early Treatment of Diabetic Retinopathy Study visual acuity scores that averaged 28.6 to 47.7 after surgery, central fixation occurred in 30% of eyes, and the appropriate graft morphology without depigmentation was found in 82% of eyes (n=21) [38]. Visual acuity scores were reported to be comparable to the results of full-thickness grafts [34,36,37]. However, the thinness of the partial graft, without the retina and the choroids, is perceived as an advantage in this graft – it easily settles after perfluorocarbon, does not require curling, enables penetration of nutrients from the choroid to the retina, and its edges do not tend to curl, which prevents the formation of subretinal membranes [38]. According to various authors [41–44], the reported long-term results of RPE/Bruch membrane PGs are not satisfactory because the achieved overall visual gain is about 1 line of best corrected visual acuity, and proliferative vitreoretinopathy complications occur in up to 45% of eyes.

Full or partial tissue transplantation is one of the current strategies for macular pathology treatment, but most grafts fail to integrate into the recipient’s bed, lose their architecture and do not function [45–47]. Moreover, allotransplants of fetal or postmortem tissue lead to rejection and the need to apply immunosuppressants and, at the same time, they raise moral and ethical concerns [30,45]. These problems are partially eliminated by the cell transplant concept [45,48].

**Cell Therapy in Retinal Pathology**

**Autologous RPE cell grafts** were performed in patients during the surgical removal of CNV in exudative AMD (CNV/AMD) [35,49] or CNV in retinal angiomatosus proliferations (CNV/RAP) [49] and can be a therapeutic option for anti-VEGF non-responders or where anti-VEGF fails to improve visual acuity (RPE tears, massive subretinal hemorrhage) [35]. After pars plana vitrectomy, nasally from the optic nerve, flat detachment of the retina was created and RPE cells were mobilized in the iatrogenic bubble by means of fluid injection. The cells were aspirated, removed by centrifugation and then counted and prepared for injection of suspension. The CNV was removed by a second paramacular retinotomy, and the suspension of RPE cells was injected under the fovea. After implantation, the cells were allowed to sink in. The procedure was finalized by applying a laser to the retinotomy and performing a perfluorocarbon-oil
exchange. In a 1-year follow-up period, visual acuity improved or stabilization occurred in 80% of patients with wet AMD and in 68% of patients with RAP [49]. However, the long-term results of autologous RPE cell grafts are not promising [32,35,50]. The technique is not viable because the grafts do not contribute to functional monolayer formation and the scattered cells atrophy. Unevenly distributed, multilayered RPE cells without their own basal lamina and extracellular matrix are unable to grow well on an aged or diseased host’s Bruch membrane, which is a crucial factor in the survival of transplanted RPE cells, their adherence and differentiation, and their ability to phagocytose photoreceptor outer segments [50–52]. The fovea requires much more stimuli than just new RPE cells in order to function properly [32]. A biostable synthetic membrane (ie, expanded polytetrafluoroethylene (ePTFE) polymer modified by ammonia gas-plasma treatment) was tested experimentally as a Bruch membrane prosthesis—a scaffold for RPE cell growth and differentiation [52]. Defuorination of the fluoro polymer increases surface hydrophilicity, incorporates surface polar groups and facilitates cell attachment [52]. ARPE-19 cells (a non-immortalized human RPE cell line that mimics the human situation), seeded on a modified ePTFE scaffold at a density of 1500 cells/mm² and cultured in the presence of retinoic acid (to promote RPE differentiation), formed a differentiated and functional monolayer capable of phagocytosing photoreceptor outer segments [52]. The scaffold serves as a carrier substrate, protected from the hostile influences of an aged and diseased Bruch membrane; facilitates cell interaction and flow of nutrients (vitamin A, glucose, fatty acid); and represents a possible treatment to repair retinal degeneration and restore vision in affected patients [50,52,53]. According to Krishna et al. [52], the biostable, biocompatible ePTFE membrane provides stable replacement of the natural Bruch membrane and long-term support for transplanted RPE cells. The membrane seems to be a better option than a synthetic biodegradable membrane or tissue-based material [50,53–57]. Despite advances in microfabrication technology, the functional results of various RPE cell transplantation techniques in humans are worse than anti-VEGF treatment and are associated with a high rate of serious complications (eg, massive hemorrhage, PVR) [35,50].

Autotransplantation of iris pigment epithelium (IPE) cells is not performed in humans because of the potential for significant damage to the iris. Non-modified IPE allotransplantation is also not performed in humans, because it does not significantly improve visual acuity [58]. However, IPE cells have become a focus of interest because in vivo they have been shown to express mRNA for proteins involved in the metabolism of retinol. They also phagocytize the external segments of photoreceptors and accumulate lipofuscin; thus, they significantly impact visual acuity [59]. Subretinal human IPE xenotransplantation was performed in rats (the Royal College of Surgeons) with iatrogenic macular dystrophy (genetically engineered gene change for the photoreceptors of tyrosine kinase, leading to inhibition of phagocytosis of the external segments of photoreceptors through RPE and lipofuscin accumulation, as well as to subsequent atrophy of photoreceptors) [59,60]. A human iris (from a cadaver) was entirely excised, and the cell suspension was injected under the retina [59]. The human IPE cell xenotransplant was shown in vivo to protect photoreceptors without any significant adverse effects; it also produced protective neurotrophic growth agents and stimulated the regeneration of photoreceptors [59]. In future, IPE cells may turn out to be useful for transferring genetic information to photoreceptors and RPE [59]. Specific retinal cells, similar to other neurons, have limited capability for proliferating and regenerating spontaneously [48].

Stem cells, as well as engineered retina (ie, retinal aggregates that are laboratory-generated from tissue-specific progenitor stem cells [PSCs]), are new therapeutic strategies for the replacement of degenerative photoreceptors and RPE cells in patients [45,57,61–79]. The multipotent stem cells differentiate into multiple, specific cell types of a lineage (meso- or exo-dermy), known as PSCs [30,48]. Multipotent stem cells can be harvested from different tissues, such as embryo, neuron, bone marrow, and eye (including the ciliary body, iris, and retina) [48]. Retinal PSCs, formed from exoderm, have the ability to differentiate into photoreceptors, RPE, Müller glial cells and bipolar cells in a favorable environment that includes growth factors and/or chemical modulators [48,80,81]. At present, research on retinal PSCs has been conducted in vitro and with animals [45,60,78,82–84], and the source of optimum retinal PSCs has not yet been determined [48]. Embryonic human stem cells can differentiate into retinal neurons that are similar to adult retinal stem cells [80], but this manner of obtaining adult stem cells in humans has raised serious moral and ethical concerns and dilemmas [45]. Neural stem cells differentiate to photoreceptors and glia in rats, but when implanted into an animal retina, often become immature and fail to express rhodopsin [85]. However, the results of xenotransplantation of human neural progenitor cells are highly promising.

A human neural progenitor xenograft was performed in 21-day-old rats with iatrogenic macular degeneration and pigment dystrophy [60]. The xenograft sustained the visual acuity of rats for 280 days [60]. Adult human stem cells found in the retina, Müller cells or RPE are considered to be the optimum source of retinal PSCs [45,61–65]. The concept of grafting both 3-dimensional (3D) cultures and differentiated retinal PSCs seems to be promising [45,70,78,79]. 3D cultures are much better suited than monolayer cultures because the graft involves the 3D structure of the recipient’s bed [45]. Retinal PSCs are cultured alone or co-cultured with RPE cells [45]. Cultured aggregates of retinal progenitors appear on approximately the 10th day of culturing. As a result of cellular bioengineering, the cultured 3D structured cells were differentiated in such a way as to create several cell lines specific for the particular tissue [45]. Photoreceptor differentiation was performed by upregulation of rhodopsin and AANAT enzyme (implicated in melanin synthesis). This differentiation was confirmed by reverse transcription-polymerase chain reaction in reference to the following factors: rod transcription factor Nr1, Nr2e3, interstitial retinal binding protein and rhodopsin kinase. Differentiation toward other cell lineages was demonstrated by the presence of tyrosine hydroxylase in amacrine and ganglion cells, as well as by the presence of calbindin and GNB3 in cone cells [45]. The resulting 3D cultured and differentiated PSC aggregates are able to blend into the degenerated bed in the recipient and are capable of producing neurotrophic factors, leading to regeneration of the photoreceptor/RPE complex and reconstruction of the subretinal
environment in retinitis pigmentosa and AMD in humans [45,48]. The development of microfabrication technology improved the delivery aspect of 3D aggregates for transplantation in an experimental study. A novel biodegradable, 3D thin-film cell encapsulation scaffold served as the carrier platform for aggregates [70]. The transplantation vehicle was constructed from thin-film 2–2.5-D polyacrolactone (PCL) layers (<10 µm) thermally bonded to form the 3-D cell encapsulation scaffold (<30 µm) with varying protrusions, cavities, pores and particles [70]. The 3D scaffold was permeable and promoted the delivery of retinal progenitor cells and their appropriate retention in subretinal space [70]. In another study [78], mouse embryonic stem cells cultured with the extracellular matrix proteins added to the medium, over a period of 9 days formed 3D spherical aggregates called embryoid bodies. Subsequent invagination of its apical surface formed an optic cup-like structure with a 2-walled structure consisting of retinal pigment epithelium and neural retina, with synaptic activities. The formation of the optic cup occurred in a self-directed way (was not caused by a lens or surface ectodermal tissues). According to several studies [78,79], self-formation of fully stratified 3D neural retina tissue from stem cells opens up a new strategy for the transplantation of the artificial retinal tissue sheets, rather than simple cell grafting. This optic-cup structure can be further induced to form an entire eye structure (lens, iris, cornea, and sclera), and can serve as the cell-culture models for drug screening and characterization of the disease phenotype. Such models may be obtained with retinal PSCs, which derived from the persons with some specific mutant genotypes associated with the diseases, such as macular degeneration or retinitis pigmentosa.

Natural retinal barriers – inhibitory extracellular matrix and cell adhesion molecules (CD44, neurocan) [86], as well as the outer limiting membrane (OLM) – that form a natural barrier between the subretinal space and the outer nuclear layer, weaken cellular host-donor integration [87,88]. Degradation of these molecules and transient chemical disruption of the OLM facilitates host-donor integration in animals [87,88]. The combined transplantation of retinal PSCs with biodegradable microspheres of poly lactic-co-glycolic acid, which deliver active matrix metalloproteinase 2, stimulated the removal of the matrix inhibitory barrier and enhanced cellular host-donor integration in mice [86]. Targeted disruption of OLM junctional proteins, Crumbs homologue 1 (Crb1) and zona occludens (ZO-1), as well as intravitreal injection of the glial toxin DL-alpha-aminoadipic acid 72 h prior to transplantation, induced transient chemical disruption of the OLM (maximal at 72 h, recovered by 2 weeks) and led to a significant increase in the number of transplanted photoreceptor precursors integrated within the outer nuclear layer in degenerated mouse retinas [87,88]. This study showed that targeted disruption of an undesirable physical barrier in the retina may be an effective and practical strategy for retinal repair. The usefulness of research on stem cells has also been confirmed by autologous non-myeloablative hematopoietic stem cell transplantation (HSCT) [89]. HSCT was shown to be effective in the therapy of autoimmune-related retinopathy and optic neuropathy syndrome (ARRON) that was resistant to conventional therapies (prednisone, methotrexate, cyclophosphamide, plasmapheresis, intravenous immunoglobulin) [89]. After HSCT, the clinical manifestations (visual acuity, visual field, electrotoretinography, and antibody activity against pig retina and pig optic nerve) of ARRON appeared to stabilize [89].

Conclusions

The techniques presented for auto- or allogenic retina transplants, both full and partial, represent the currently available surgical alternatives in the treatment of neovascular and atrophic macular diseases. However, retina transplant requires complicated vitreoretinal surgery and in some cases might be followed by delayed reperfusion of the graft.

The difficulty of retina transplantation lies in the highly specific nature of the complex and “demanding” neuronal tissue. Stem cell transplantation in retinal diseases is of increasing importance [90], but further laboratory tests in genetic engineering and animal testing are required to find an optimal source of PSCs for RPE cells and photoreceptors [45,48,60,91,92]. Stem cell transplantation also raises new ethical dilemmas that require further consideration [93].

Abbreviations

AMD – age-related macular degeneration; ARRON – autoimmune-related retinopathy and optic neuropathy; CNV/AMD – choroidal neovascularization in age-related macular degeneration; CNV/RAP – choroidal neovascularization in retinal angiomatosus proliferations; 3D – three-dimensional; ePTFE – expanded polytetrafluoroethylene; FMT – full macular translocation; HSCT – hematopoietic stem cell transplantation; IPE – iris pigment epithelium; OLM – outer limiting membrane; PG – patch graft; PSCs – progenitor stem cells; PVR – proliferative vitreous retinopathy; RPE – retinal pigment epithelium; VEGF – vascular endothelial growth factor.

References:

1. Detrick B, Hooks JJ: Immune regulation in the retina. Immunol Res, 2010; 47: 155–61
2. Nussenblatt RB, Liu B, Li Z: Age-related macular degeneration: an immunologically-driven disease. Curr Opin Investig Drugs, 2009; 10: 434–42
3. Ding X, Patel M, Chan CC: Molecular pathology of age-related macular degeneration. Prog Retin Eye Res, 2009: 28: 1–18
4. Cruess AF, Zlateva G, Pleil AM, Wirostko B: Photodynamic therapy with verteporfin in age-related macular degeneration: systematic review of efficacy, safety, treatment modifications and pharmacoeconomic properties. Acta Ophthalmol, 2009; 87(2): 118–32
5. Schmidt-Erfurth U, Kiss C, Sacu S: The role of choroidal hypoperfusion associated with photodynamic therapy in neovascular age-related macular degeneration and the consequences for combination strategies. Prog Retin Eye Res, 2009; 28(2): 145–54
6. Shah GK, Sang DN, Hughes MS: Verteporfin combination regimens in the treatment of neovascular age-related macular degeneration. Retina, 2009; 29(2): 133–48
7. Ruiz-Moreno JM, Montero JA: Combined treatment of exudative age-related macular degeneration with photodynamic therapy and intravitreal triamcinolone. Clin Ophthalmol, 2009; 2(1): 71–75
8. Brzozowski RA: Antiangiogenic approaches to age-related macular degeneration today. Ophthalmol Res, 2009; 41(1): S15–23
9. Sahel JA, Mohanty-Said S, Leaveland T et al: Rod-cone interdependence: implications for therapy of photoreceptor cell diseases. Prog Brain Res, 2001; 131: 649–61
10. La Vail MM, Yasumura D, Matthes MT et al: Ribozyme rescue of photoreceptor cells in P23H transgenic rats: long-term survival and late-stage therapy. Proc Natl Acad Sci USA, 2000; 97(2): 11488–93
11. Parini MT, Phillips MJ, Yin H et al: Neuroprotective effect of subretinal implants in the RCS rat. Invest Ophthalmol Vis Sci, 2005; 46: 674–82
12. Niederkorn J, Wang S: Immune privilege of the eye and fetus: paralel universes? Transplantation, 2005; 80: 1139–44
13. Streilein JW: Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol, 2003; 3: 879–89
14. Otani A, Dorrell MI, Kinder K et al: Rescue of retinal degeneration by intravitreally injected adult bone marrow-derived lineage-negative hematopoietic stem cells. J Clin Invest, 2004; 114: 765–74
15. Bennett J, Tanabe T, Sun D et al: Photoreceptor cell rescue in retinal degeneration (rd) mice by in vivo gene therapy. Nat Med, 1996; 2: 649–54
16. Streilein JW, Stein-Streilein J: Does innate immune privilege exist? J Leukoc Biol, 2000; 67: 479–87
17. West EL, Pearson RA, Barker SE et al: Long-term survival of photoreceptors transplanted into adult mouse retinas requires immune modulation. Stem Cells, 2010; 28: 1997–2007
18. Horii J, Vega JL, Masli S: Review of ocular immune privilege in the year 2010: modifying the immune privilege of the eye. Ocul Immunol Inflamm, 2010; 18: 325–35
19. Sugita S: Role of ocular pigment epithelial cells in immune privilege. Arch Immunol Ther Exp, 2009; 57: 265–68
20. Griffith TS, Yu X, Herndon JM: CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunotolerance. Immunity, 1996; 5: 7–16
21. Sabroe I, Parker LG, Dower SK, Whyte MK: The role of TLR activation in inflammation. J Pathol, 2008; 214: 126–35
22. Kumar MV, Nagineni CN, Panjwani N, Cao Z: Participation of pigment epithelium in innate immunity in the retina: toll-like receptor (TLR) signaling in human retinal pigment epithelial cells. J Neuroimmunol, 2004; 135: 7–15
23. Ishida K, Panjwani N, Cao Z: Participation of pigment epithelium in ocular immune privilege. 3. Epithelia cultured from iris, ciliary body, and retina suppress T-cell activation by partially non-overlapping mechanisms. Ocul Immunol Inflamm, 2003; 11: 91–105
24. Sugita S, Utsu Y, Horie S: T cell suppression by programmed cell death 1 ligand 1 on retinal pigment epithelial during inflammatory conditions. Invest Ophthalmol Vis Sci, 2009; 50: 2682–70
25. Sugita S, Horie S, Nakamura O: Retinal pigment epithelium-derived cytotoxic cytotoxic T lymphocyte antigen-2 induces TGFB-producing T regulatory cells. J Immunol, 2008; 181: 7525–36
26. Ghosh F, Rauer O, Arnér K: Immune privilege of allogeneic neuroretinal transplants in the subconjunctival space. Graefes Arch Clin Exp Ophthalmol, 2008; 246: 1715–22
27. Joussen AM, Joeres S, Fawzy N: Autologous transplantation of the choroid and retinal pigment epithelium in patients with geographic atrophy. Ophthalmology, 2007; 114: 551–60
28. Radtke ND, Aramant RB, Petry HM et al: Vision improvement in retinal degeneration patients by implantation of retina together with retinal pigment epithelium. Arch Clin Invest, 2004; 114: 130–135
29. Reina SB, Yeh JJH, Lee JS et al: Characterization of retinal ganglion cell activities evoked by temporally patterned electrical stimulation for the development of stimulus encoding strategies for retinal implants. Research Report Brain Research, 2009; 1275: 33–42
30. Zarbin MA: Retinal pigment epithelium-retina transplantation for retinal degenerative disease. Am J Ophthalmol, 2008; 146: 151–53
31. Chen FK, Patel PJ, Uppal GS et al: A comparison of macula translocation with patch graft in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci, 2009; 50: 1848–55
32. Ceregha MG, Polonini B, Bellesi E, Pertile G: Surgery for CNV and autologous choroidal RPE patch transplantation: exposing the submacular space. Graefes Arch Clin Exp Ophthalmol, 2010; 248: 57–67
33. MacLaren RE, Uppal GS, Balaggan KS: Autologous transplantation of the retinal pigment epithelium and choroid in the treatment of neovascular age-related macular degeneration. Ophthalmology, 2007; 114: 561–70
34. Maas J, Hau L, Wang C, Dou H et al: Autologous transplantation of retinal pigment epithelium–Bruch’s membrane complex for hemorrhagic age-related macular degeneration. Invest Ophthalmol Vis Sci, 2009; 50: 2975–81
35. Maas J, Missotten T, Mulder P, van Meurs JC: Influence of intraoperative course on visual outcome after an RPE-choroid translocation. Invest Ophthalmol Vis Sci, 2008; 49: 758–76
36. Hu Y, Zhang T, Wu J, Li Y et al: Autologous transplantation of RPE with partial-thickness choroid after mechanical debridement of Bruch membrane in the rabbit. Invest Ophthalmol Vis Sci, 2008; 49: 3185–92
37. Tezel TH, Del Priore LV, Berger AS et al: Adult retinal pigment epithelial transplantation in exudative-age related macular degeneration. Am J Ophthalmol, 2007; 143: 584–95
38. Binder S, Stanzel BV, Krebs I et al: Transplantation of RPE in AMD. Prog Retin Eye Res, 2007; 26: 516–54
39. da Cruz L, Chen FK, Ahmad A et al: RPE transplantation and its role on retinal disease. Prog Retin Eye Res, 2007; 26: 598–635
40. van Meurs JC, van den Biesen PR: Autologous retinal pigment epithelium and choroids translocation in patients with exudative age-related macular degeneration; short term follow up. Am J Ophthalmol, 2003; 136: 688–95
41. Dutt K, Cao Y: Engineering retina from human retinal progenitors (cell lines). Tissue engineering: Part A, 2009; 15(6): 1401–13
42. Humayun MS, Prince M, de Juan E et al: Morphometric analysis of the extramacular retina from postmortem eyes with retinitis pigmentosa. Invest Ophthalmol Vis Sci, 199; 40: 143–48
43. Milam AH, Li ZY, Faris RN: Histopathology of the human retina in retinitis pigmentosa. Prog Retin Eye Res, 1998; 17: 175–205
44. Bi YT, Feng DF, Pan DCH: Stem/progenitor cells: A potential source of retina-specific cells for retinal repair. Neuroscience Research, 2009; 65: 215–21
45. Krebs I, Binder S, Stolba U, Kellner L et al: Subretinal surgery and transplantation of autologous pigment epithelial cells in retinal angiomatos proliferation. Acta Ophthalmol, 2008; 86: 504–9
46. Binder S: Scaffolds for retinal pigment epithelium (RPE) replacement therapy. Br J Ophthalmol, 2011; 95: 441–42
47. Lee E, MacLaren RE: Sources of retinal pigment epithelium (RPE) for replacement therapy. Br J Ophthalmol, 2011; 95: 445–49
48. Krishna Y, Sheridan C, Kent D et al: Expanded polytetrafluoroethylene as a substrate for retinal pigment epithelial cell growth and transplantation in age-related macular degeneration. Br J Ophthalmol, 2009; 93: 569–73
49. Hynes SR, Lask EB: A tissue-engineered approach towards retinal repair: scaffolds for cell transplantation to the subretinal space. Graefes Arch Clin Exp Ophthalmol, 2010; 248: 765–78
50. Thomson HA, Treiharne AJ, Backholer LS: Biodegradable poly(ethylene ester) blended microphores as suitable carriers for retinal pigmented epithelial cell transplantation. J Biomed Mater Res A, 2010; 95: 1233–43
51. Lakowski J, Baron M, Bainbridge J et al: Cone and rod photoreceptor transplantation in models of the childhood retinopathy Leber congenital amaurosis using flow-sorted Cx43positive donor cells. Hum Mol Genet, 2010; 19: 4545–59
52. Thomson HA, Treiharne AJ, Walker P et al: Optimisation of polymer scaffolds for retinal pigment epithelium (RPE) cell transplantation. Br J Ophthalmol, 2011; 95: 563–68
53. Altab U, Jiang C, Tucker B et al: Growth kinetics and transplantation of human retinal progenitor cells. Exp Eye Res, 2009; 89: 301–10
54. Aisenbrey S, Lafont BA, Smurran P, Hilgers RD et al: Iris pigment epithelial transplantation in the treatment of exudative macular degeneration: a 3 year follow-up. Arch Ophthalmol, 2006; 124: 183–88
55. Thumann G, Salz AK, Walter P, Johnsen S: Preservation of photoreceptors in dystrophic RCS rats following allo- and xenotransplantation of RPE cells. Graefes Arch Clin Exp Ophthalmol, 2009; 247: 563–69
56. Chen FK, Uppal GS, Rubin GS et al: Evidence of retinal function using microperimetry following autologous retinal pigment epithelium-choroid graft in macular dystrophy. Invest Ophthalmol Vis Sci, 2008; 49: 5143–50
57. Klassen H, Ziaian B, Kirov II et al: Isolation of retinal progenitor cells from postmortem human tissue and comparison with autologous brain progenitors. J Neurosci, 2004; 27: 334–43
62. Bhattacharya S, Jackson JD, Das AV et al: Direct identification and enrichment of retinal stem cells/progenitors by Hoechst dye efflux assay. Invest Ophthalmol Vis Sci, 2005; 44: 2764–73
63. Fischer AJ, Reh TA: Muller glia are a potential source of neural regeneration in the postnatal chicken retina. Nat Neurosci, 2001; 4: 247–52
64. Ahmad I, Tang L, Pham H: Identification of neural progenitors in the adult mammalian eye. Biochem Biophys Res Commun, 2000; 270: 517–21
65. Troppe V, Coles BL, Chiasson BJ et al: Retinal stem cells in the adult mammalian eye. Science, 2000; 287: 2032–36
66. Marchetti V, Krohne TU, Friedlander DF, Friedlander M: Stemming vision loss with stem cells. J Clin Invest, 2010; 120: 3012–21
67. Ballios BG, van der Kooy D: Biology and therapeutic potential of adult retinal stem cells. Can J Ophthalmol, 2010; 45: 542–54
68. Dahlanmann-Noor A, Vijay S, Jezarai H et al: Current approaches and future prospects for stem cell rescue and regeneration of the retina and optic nerve. Can J Ophthalmol, 2010; 45: 333–41
69. Hou HY, Liang HL, Wang YS et al: A therapeutic strategy for choroidal neovascularization based on recruitment of mesenchymal stem cells to the sites of lesions. Mol Ther, 2010; 18: 1837–45
70. Sodha S, Wall K, Redenti S et al: Microfabrication of a three-dimensional polycaprolactone thin-film scaffold for retinal progenitor cell encapsulation. J Biomater Sci Polym Ed, 2011; 22: 445–56
71. West EL, Pearson RA, MacLaren RE, Sowden JC, Ali RR: Cell transplantation strategies for retinal repair. Prog Brain Res, 2009; 175: 3–21
72. Meyer JS, Howden SE, Wallace KA et al: Optic vesicle-like structures derived from human Pluripotent Stem Cells facilitate a customized approach to retinal disease treatment. Stem Cells, 2011; 29(8): 1206–18
73. Howden SE, Gore A, Li Z et al: Genetic correction and analysis of induced pluripotent stem cells from a patient with gyrate atrophy. Proc Natl Acad Sci USA, 2011; 108: 6537–42
74. Gamm DM, Meyer JS: Directed differentiation of human induced pluripotent stem cells: a retina perspective. Regen Med, 2010; 5: 315–17
75. Meyer JS, Shearer RL, Capowski EE et al: Modeling early retinal development with human embryonic and induced pluripotent stem cells. Proc Natl Acad Sci USA, 2009; 106: 16901–11
76. Carr AJ, Vugler AA, Hijikata ST et al: Protective effects of human iPS-derived retinal pigment epithelium cell transplantation in the retinal dystrophic rat. PLoS One, 2009; 4(12): e8152
77. Sowden JC, Ali RR: Stem cell therapy for blindness: new developments and implications for the future. Expert Rev Ophthalmol, 2011; 6(1): 1–3
78. Zhang K, Ding S: Stem Cells and Eye Development. N Engl J Med 2011; 29(1): 370–72
79. Eiraku M, Takata N, Ishibashi H et al: Self-organizing optic-cup morphogenesis in three-dimensional culture. Nature, 2011; 472(7): 1–7
80. Lamba DA, Karl MO, Warc CB, Reh TA: Efficient generation of retinal progenitor cells from human embryonic stem cells. Proc Natl Acad Sci USA, 2006; 103: 12769–74
81. Gamm DM, Nelson AD, Svendsen CN: Human retinal progenitor cells grown as neurospheres demonstrate time-dependent changes in neuronal and glial cell fate potential. Ann NY Acad Sci, 2005; 1049: 107–17
82. Blong CC, Jean CJ, Yeo JY et al: Differentiation and behavior of human neural progenitors on micropatterned substrates and in the developing retina. J Neurosci Res, 2010; 88: 1443–56
83. Hasan SM, Vugler AA, Miljan EA et al: Immortalized human fetal retinal cells retain progenitor characteristics and represent a potential source for the treatment of retinal degenerative disease. Cell Transplant, 2010; 19: 1291–306
84. Zhang Y, Wang W: Effects of bone marrow mesenchymal stem cell transplantation on light-damaged retina. Invest Ophthalmol Vis Sci, 2010; 51: 3742–48
85. Young MJ, Lee J, Whiteman SJ et al: Neuronal differentiation and morphological integration of hippocampal progenitor cells transplanted to the retina of immature and mature dystrophic rats. Mol Cell Neurosci, 2010; 46: 197–205
86. Yao J, Tucker BA, Zhang X et al: Robust cell integration from co-transplantation of biodegradable MMP2-PLGA microspheres with retinal progenitor cells. Biomaterials, 2011; 32: 1041–50
87. Pearson RA, Barber AC, West EL et al: Targeted disruption of outer limiting membrane junctional proteins (Crb1 and ZO-1) increases integration of transplanted photoreceptor precursors into the adult wild-type and degenerating retina. Cell Transplant, 2010; 19: 487–503
88. West EL, Pearson RA, Tischnerut M et al: Pharmacological disruption of the outer limiting membrane leads to increased retinal integration of transplanted photoreceptor precursors. Exp Eye Res, 2008; 86: 601–11
89. Oyama Y, Burt RK, Thirkill C et al: A case of autoimmune-related retinopathy and optic neuropathy syndrome treated by autologous hematopoietic stem cell transplantation. J Neuroophthalmol, 2009; 29(1): 43–49
90. Park DH, Eve D, Borlongan C et al: From the basics to application of hematopoietic stem cell transplantation. J Neuroophthalmol, 2009; 29(1): 43–49
91. Alberti E, Los M, Garcia R et al: Prolonged survival and expression of neural markers by bone marrow-derived stem cells transplanted into brain lesions. Med Sci Monit, 2009; 15(2): BR47–54
92. Park DH, Borlongan C, Eve D, Sanberg P: The emerging field of cell therapy, a steppingstone to the conquest of neurodegeneration: A meeting report. Med Sci Monit, 2009; 15(2): RA23–31
93. Gilbert D: The future of human embryonic stem cell research: addressing ethical conflict with responsible scientific research. Med Sci Monit, 2004; 10(5): RA99–103